Please login to the form below

Not currently logged in
Email:
Password:

Pharma is target of news hoax

News service, Business Wire, has changed its submission policies following a bogus news release concerning Javelin Pharmaceuticals

Business Wire, the well-known news release service, has changed its submission policies after it inadvertently disseminated a bogus news release concerning Massachusetts-based Javelin Pharmaceuticals, a drug-development company focused on pain management.

The June 18, 2010 news release was headlined "US Supreme Court split - rules in favor of Big Pharma" and listed Javelin as the issuer. However, the release was actually a hoax submitted by an unknown third party claiming to be a company representative.

Javelin notified Business Wire, and the news service issued a retraction on the morning of June 19, 2010. The pharma firm said that it has verified that the company's email system was not used for the hoax.

Business Wire said that law enforcement agencies have been contacted and the hoax is now the subject of a Federal criminal investigation. In addition, the news service said that, effective immediately, all news releases will have to be submitted via "BW Connect" the company's proprietary order-entry system, rather than by email.

The system, which has been operational since 1998 and is already used for the bulk of the releases that are submitted, receives an annual independent security audit, Business Wire noted. The company said it had planned to make the change-over from allowing e-mail submissions in August, but has expedited it following the hoax.

22nd June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics